Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | RXRA | P19793 | 7/20 | 0.50 |
| ▸ | RXRB | P28702 | 6/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11392894 | 0.82 | CA2 (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL7129810 | 0.82 | ALDH1A1 (0.50) | ALDH1A1RXRARXRBNR4A2NPC1 | |
| SCHEMBL12384217 | 0.80 | CA2 (0.57) | ALDH1A1RXRARXRBPOLBTSHR | |
| SCHEMBL29210313 | 0.79 | HDAC6 (0.55) | CA1CA2 | |
| SCHEMBL121593 | 0.79 | LOXL2 (0.58) | ALDH1A1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL9710253 | 0.79 | KMT2A (0.69) | ALDH1A1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL9439348 | 0.79 | ALDH1A1 (0.69) | ALDH1A1RXRARXRBNR4A2NPC1 | |
| SCHEMBL437438 | 0.79 | IDO1 (0.50) | CA2 | |
| SCHEMBL7276079 | 0.78 | FOLH1 (0.56) | NR4A2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL16599181 | 0.78 | TSHR (0.52) | ALDH1A1RAB9ASMN1; SMN2TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029997-B2 | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180170951-A1 | AMIDE-LINKED EP4 AGONIST-BISPHOSPHONATE COMPOUNDS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2018-06-21 | — | — | US | disclosed |
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2017-05-04 | — | — | US | disclosed |
| US-7706658-B2 | Copolymer and polymerizable composition | FUJIFILM CORPORATION (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20090116808-A1 | COPOLYMER AND POLYMERIZABLE COMPOSITION | FUJIFILM CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| WO-2007004743-A1 | COPOLYMER AND POLYMERIZABLE COMPOSITION | FUJIFILM CORPORATION (JP) | 2007-01-11 | — | — | WO | disclosed |
| EP-1256575-B1 | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1560810-A1 | BIFUNCTIONAL PHENYLISO(THIO)CYANATES; METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-1999007702-A1 | SUBSTITUTED HERBICIDE TETRAZOLINONECARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998054139-A1 | METHOD FOR PRODUCING SUBSTITUTED THIOPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998038169-A1 | SUBSTITUTED 3-PHENYL PYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998011072-A1 | SUBSTITUTED THIOPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998007700-A1 | SUBSTITUTED 2-PHENYLPYRIDINE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998007720-A1 | SUBSTITUTED 2-ARYLPYRIDINE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998005649-A1 | SUBSTITUTED 3-PHENYL PYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-12 | — | — | WO | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170951-A1 | AMIDE-LINKED EP4 AGONIST-BISPHOSPHONATE COMPOUNDS AND USES THEREOF | PTGER4, ENPP2, PTGER3 | ALDH1A1 2130/4885RXRA 868/4885RXRB 807/4885 |
| US-20170121297-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | GSK3B, HDAC1, HDAC3 | ALDH1A1 766/4885RXRA 2521/4885RXRB 2426/4885 |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | ALDH1A1 2368/4885RXRA 3945/4885RXRB 3546/4885 |
| US-10029997-B2 | Compositions and methods for treating cancers | HDAC3, HDAC1, GSK3B | ALDH1A1 907/4885RXRA 2518/4885RXRB 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.